SNDX Stock Analysis: Buy, Sell, or Hold?
SNDX - Syndax Pharmaceuticals, Inc.
$20.43
0.82 (4.18%)
▲
5d:
+10.13%
30d:
+2.46%
90d:
-14.95%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Smart Money Accumulation
None View Scanner →
Strength: 7.0/10
Get Alerted When SNDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SNDX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SNDX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SNDX is currently trading at $20.43, which is considered extended relative to its 30-day fair value range of $17.97 to $19.83. From a valuation perspective, the stock is trading at a discount (Forward PE: -37.5) compared to its historical average (126.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SNDX is in a strong uptrend. The price is approaching resistance at $20.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: SNDX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.00 (+98.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SNDX is in a strong uptrend. The price is approaching resistance at $20.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: SNDX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.00 (+98.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.97 -
$19.83
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 98.9% below Wall St target ($39.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$17.97 -
$19.83
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$17.31
Resistance Level
$20.72
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-37.49
Wall Street Target
$39.00
(+98.9%)
Revenue Growth (YoY)
223.6%
Profit Margin
-112.0%
PE vs Historical
-37.5 vs 126.3
CHEAP
Share & Embed Analysis
Last updated: June 24, 2026 1:06 PM ET
Data refreshes hourly during market hours. Next update: 2:06 PM
Data refreshes hourly during market hours. Next update: 2:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Keith A Goldan
SELL
3410 shares
2026-02-09
Michael A Metzger
SELL
17159 shares
2026-02-09
Keith A Goldan
SELL
2082 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced SNDX Option Strategies
Professional options setups generated by AI based on today's SNDX price and gamma walls.
